<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460876</url>
  </required_header>
  <id_info>
    <org_study_id>14711603062</org_study_id>
    <nct_id>NCT00460876</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Periocular Topotecan in Retinoblastoma</brief_title>
  <official_title>Toxicity and Activity of Periocular Topotecan in Children With Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital JP Garrahan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital JP Garrahan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-escalation study aimed to assess the toxicity (and marginally the activity) of
      periocular topotecan in patients with relapsed-resistant retinoblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with bilateral retinoblastoma who have relapsed after attempts of conservative
      therapy with standard regimens such as carboplatin, etoposide, vincristine and external beam
      radiotherapy who face immediate enucleation of their single remaining eye are eligible for
      this protocol. Starting dose of topotecan will be 0.5 mg and dose escalation will be done by
      the accelerated titration method. Any Grade 3 ocular toxicity or grade 4 non ocular toxicity
      will be designed as the dose limiting toxicity. Grade 2 scleral toxicity will be considered
      for DLT. In case of grade 2 ocular toxicity or grade 3 systemic toxicity, the escalation dose
      will be 0.25 mg. Maximal dose will be 2 mg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate, description of toxicity, pharmacokinetic profile</measure>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Retinoblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group Vb (Reese Ellsworth)

          -  Relapsed or progressed after carboplatin-based regimens and external beam radiotherapy

          -  Enucleation of the contralateral eye

          -  Normal renal and liver function

        Exclusion Criteria:

          -  Presence of glaucoma, rubeosis iridis, anterior chamber extension

          -  Extraocular disease

          -  Adequate follow up impossible for social reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo L Chantada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital JP Garrahan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital JP Garrahan</name>
      <address>
        <city>Buenos Aires</city>
        <state>CF</state>
        <zip>C1245AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2007</study_first_submitted>
  <study_first_submitted_qc>April 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2007</study_first_posted>
  <last_update_submitted>April 30, 2008</last_update_submitted>
  <last_update_submitted_qc>April 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hospital JP Garrahan</name_title>
  </responsible_party>
  <keyword>topotecan</keyword>
  <keyword>periocular</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

